All AbMole products are for research use only, cannot be used for human consumption.
Tolvaptan (OPC-41061) is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28uM for the inhibition of AVP-induced platelet aggregation. Tolvaptan (OPC-41061) is used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan (OPC-41061) is also in fast-track clinical trials for polycystic kidney disease. Treatment with t tolvaptan (OPC-41061) causes rapid and sustained body weight reductions concurrent with increases in urine output, improves and/or normalizes serum sodium in hyponatremic patients, reduces signs and symptoms of congestion and increases thirst. However, tolvaptan (OPC-41061) has not been shown to decrease heart failure re-hospitalization or mortality. As an adjunct to standard therapy, tolvaptan (OPC-41061) is unique in that it is virtually the only novel agent tested in patients hospitalized for acute heart failure syndrome (AHFS) to reach its primary end point for short-term efficacy without causing deleterious side effects.
J Med Chem. 2022 Jun 9;65(11):7717-7728.
Long Residence Time at the Vasopressin V2 Receptor Translates into Superior Inhibitory Effects in Ex Vivo and In Vivo Models of Autosomal Dominant Polycystic
Tolvaptan purchased from AbMole
| Molecular Weight | 448.94 |
| Formula | C26H25ClN2O3 |
| CAS Number | 150683-30-0 |
| Solubility (25°C) | DMSO 60 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] Olivier Bonny, et al. Clinical use of tolvaptan: a 2021 review
[3] Hannah A Blair. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
| Related Vasopressin Receptor Products |
|---|
| Mozavaptan
Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. |
| Conivaptan hydrochloride
Conivaptan hydrochloride is a non-peptide vasopressin receptor antagonist, which can inhibit V1A receptor in rat liver and V2 receptor in kidney with Ki values of 0.48 and 3.04 nM, respectively. |
| Atosiban Acetate
Atosiban (RW22164; Tractocile) Acetate is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTra). Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. |
| L-371,257
L-371,257 is a potent and selective oxytocin receptor antagonist. |
| RG7713
RG7713 (RO5028442) is a highly effective and selective brain-osmotic vasopressin 1A (V1a) receptor antagonist with Ki values of 1 nM (hV1a) and 39 nM (mV1a). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
